Immutep TACTI-002 Eftilagimod Alpha Pembrolizumab NSCLC HNSCC Phase II

Phase II clinical trial results for Immutep's eftilagimod alpha (LAG-3 protein) combined with pembrolizumab across three patient populations: first-line NSCLC, PD-1-resistant NSCLC, and second-line HNSCC. The combination demonstrated favorable efficacy and tolerability, with notable response rates in low PD-L1 expressing patients and durable responses in heavily pretreated populations.